Financial newsfor AI agents.

Market-moving stories, structured for trading automations. Plug into Claude Desktop, Cursor, or your own agent in minutes.

10,000+

Crawled and deduplicated across the open web. The strongest candidates get a full AI pass with a 1–10 relevance score and per-ticker analysis.

6,900+

Distinct publisher domains scanned in the last 30 days.

<1 in 5

Only the best clear the relevance floor with a verified ticker. The rest is filtered out.

~6 min

Median from EDGAR publication to an enriched, ticker-tagged row, covering insider trades (Form 4) and corporate actions (8-K).

All of it can come to you. News alerts land in Telegram, email, or a webhook the moment a story clears your filters, and the tickers, categories, and relevance threshold are yours to set.

Set up alerts

Built for AI agents and trading bots.

$LLYMed

An Amino Acid Dispute Between Eli Lilly and the FDA Could Delay Cheaper Retatrutide by Years

Eli Lilly and the FDA are in a legal dispute over whether retatrutide, a triple-hormone injection for obesity, is a biologic or a drug. The classification affects market exclusivity, with biologics having 12 years and drugs 5 years. Lilly claims retatrutide has 41 amino acids, meeting the biologic threshold, but the FDA disagrees. The outcome could delay cheaper versions of the drug by years, impacting patients and insurers. Lilly plans to file for approval in early 2027, but the timeline may sh

$LVSMed

LVS keeps Macau promotional spending high in push for premium players

Las Vegas Sands (LVS) plans to maintain high promotional spending in Macau to attract premium players, despite potential short-term earnings impact. According to Seaport Research Partners, LVS aims to regain market share in the competitive casino market, with no plans to reduce spending in the near future. The company operates five resorts in Macau through its Sands China subsidiary.

$GILDLow

FDA Decision Due Thursday on a Two-Drug HIV Pill Designed to Simplify Complex Daily Regimens

The FDA has a target date of August 27, 2026, to decide on Gilead Sciences' application for a once-daily two-drug HIV tablet combining bictegravir and lenacapavir. The decision could offer a new option for adults with HIV who are already virologically suppressed. The application is supported by two phase 3 trials, ARTISTRY-1 and ARTISTRY-2, which showed comparable efficacy and no significant safety concerns. The pill's approval would not cover people starting treatment for the first time or thos

$BTC-USDMed

Bitcoin Wakes Up as Treasury Blinks: Is the Great Catch

Bitcoin surged to $78,800, driven by $4B in short liquidations and $1.92B in U.S. spot Bitcoin ETF inflows, led by BlackRock's IBIT. Institutional demand and broader crypto market gains followed. Bitcoin remains 40% below its 2025 peak but may catch up as traditional markets rally. Treasury's bond buyback plan aimed to lower yields but had limited impact, signaling potential discomfort with high yields, which could support Bitcoin's case.

Med

Trump's 50% Canada tariff threat rattles Michigan auto makers and workers near Detroit

The Trump administration proposed a 50% tariff on Canadian auto parts starting in 2027, raising concerns among Michigan auto suppliers. CITIC Dicastal CEO Dale Hadel warned of potential disruptions, as his company relies on Canadian aluminum. Workers and industry experts fear job losses and inflation. Canada plans retaliatory tariffs. Ford, Stellantis, and GM have not commented.

$NVDALowAI 8/10

Taiwan indicts Nvidia manager after chip smuggling probe

Taiwanese prosecutors indicted a senior Nvidia manager and eight others, including two Super Micro employees, for allegedly smuggling advanced AI chips to China, circumventing US trade restrictions. The group attempted to ship 74 servers with high-end B300 chips and 56 others were seized. Prosecutors seek five years for the Nvidia manager, described as the 'core figure'. Both Nvidia and Super Micro deny wrongdoing and are cooperating with authorities.

The same feed, as an API.

The same scored news feed that powers alphai is available as a REST API, and as an MCP server for Claude Desktop, Cursor, and any other agent host. Articles arrive enriched and linked to tickers in real time.

  • Real-time + historical news
  • Per-ticker filters and search
  • Relevance-scored 1–10
  • Free tier + paid scale

Dropping it into an existing stack? The Python and n8n quick starts are copy-paste.

curl https://api.alphai.io/api/news/ \
  -H "Authorization: Bearer ${ALPHAI_API_KEY}" \
  -G -d "symbol=NVDA"

# → {
#   "results": [{
#     "original": {
#       "title": "Nvidia export curbs tighten...",
#       "summary": "The White House is expected to...",
#       "time_published": "2026-04-18T14:32:00Z"
#     },
#     "enrichment": {
#       "category": "macro",
#       "tickers": ["NVDA"],
#       "relevance_score": 9
#     }
#   }, ...],
#   "next_cursor": "MjAyNi0wNC0xOFQxNDozMjowMHw0Mg=="
# }

Three plans. One feed.

Free reads the feed and probes the APIs. Paid plans drop the ads and scale up the rate.

Free

$0forever
  • Unlimited articles on the website
  • REST + MCP: 20 / min · 100 / day each, 1 API key
  • Sponsored placements visible
Start for free

Basic

$2.99$7.99/month
  • No ads, unlimited watchlist
  • Daily digest of ticker alerts
  • REST API: 60 / min · 10,000 / day, 1 key
  • MCP server: 60 / min · 10,000 / day
Get started

Pro

$9.99$24.99/month
  • Everything in Basic
  • REST API: 150 / min · 100,000 / day, 5 keys
  • MCP server: 150 / min · 100,000 / day + bulk
Get started

Subscribe now and keep this rate for as long as you stay subscribed. We will not raise it for you.

Don’t want to watch the feed? Follow a ticker and we’ll deliver a daily digest of everything that clears your relevance bar, so you don’t have to check back.

Set up alerts